Janux Therapeutics, Inc.
JANXNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $10.0M | $10.6M | $8.1M | $8.6M | $3.6M | $0 |
| Operating income | −$157.7M | −$98.8M | −$73.0M | −$67.1M | −$32.9M | −$4.8M |
| Net income | −$113.6M | −$69.0M | −$58.3M | −$63.1M | −$32.7M | −$6.8M |
| Total assets | $1.00B | $1.06B | $380.4M | $364.0M | $379.8M | $16.2M |
| Total liabilities | $44.7M | $38.7M | $36.1M | $43.3M | $13.5M | $9.2M |
| Equity | $956.8M | $1.02B | $344.3M | $320.7M | $366.3M | −$14.6M |
| EPS (diluted) | $-1.83 | $-1.28 | $-1.32 | $-1.52 | $-1.39 | — |
| Shares out. | 59.1M | 51.7M | 41.8M | 41.6M | 41.2M | 1.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −1576.7%
- Net margin
- −1136.3%
- Return on equity
- −11.9%
- Return on assets
- −11.3%
- Return on capital (ROCE)
- −16.1%
- Liabilities / assets
- 4.5%
- Debt / equity
- 0.05×
- Book value / share
- $16.19
- Revenue growth (YoY)
- −5.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 26.48safe
- Accruals / assets
- −3.1%clean
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 4 warning● 3 good- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Active Not Recruitingreadout ~2026-07-31Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
- EARLY_Phase 1Recruitingreadout ~2026-10Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.
- Phase 1Recruitingreadout ~2027-07Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- Phase 1Recruitingreadout ~2028-05Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Dobek MariaOfficer — Vice President, Accounting | May 11, 2026 | Sell | 2,038 | $14.17 |
| Go WilliamOfficer — Chief Medical Officer | Feb 2, 2026 | Grant | 44,000 | $0.00 |
| Meyer Andrew HollmanOfficer — Chief Business Officer | Jan 2, 2026 | Sell | 1,879 | $13.73 |
| Diraimondo ThomasOfficer — Chief Scientific Officer | Jan 2, 2026 | Sell | 2,505 | $13.73 |
| Campbell David AlanOfficer — President and CEO | Jan 2, 2026 | Sell | 8,072 | $13.73 |
| Winter Charles M.Officer — Chief Technical Officer | Jan 2, 2026 | Sell | 2,401 | $13.73 |
| Mciver ZachariahOfficer — Chief Medical Officer | Jan 2, 2026 | Sell | 2,714 | $13.73 |
| Doyle Janeen NoelOfficer — Chief Corp. & Bus. Dev. Ofcr | Jan 2, 2026 | Grant | 36,000 | $0.00 |
| Dobek MariaOfficer — Vice President, Accounting | Jan 2, 2026 | Sell | 1,462 | $13.73 |
| Meyer Andrew HollmanOfficer — Chief Business Officer | Dec 1, 2025 | Option exercise | 3,333 | $10.59 |
| Meyer Andrew HollmanOfficer — Chief Business Officer | Nov 14, 2025 | Option exercise | 3,333 | $10.59 |
| Meyer Andrew HollmanOfficer — Chief Business Officer | Oct 28, 2025 | Option exercise | 9,999 | $4.21 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 7.8M | 9.7 | -1.3% |
| Apr 30, 2026 | 7.9M | 7.4 | +6.6% |
| Apr 15, 2026 | 7.4M | 8.3 | -3.9% |
| Mar 31, 2026 | 7.7M | 5.5 | -22.7% |
| Mar 13, 2026 | 10.0M | 12.0 | +0.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 7, 2026
- Director / officer changeApr 28, 2026
- Results of operationsFeb 26, 2026
- Entered a material agreement · Regulation FD disclosureJan 22, 2026
- Results of operationsNov 6, 2025
- Director / officer changeSep 19, 2025
- Results of operationsAug 7, 2025
- Shareholder voteJun 13, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SCHEDULE 13G/AMay 15, 2026
- 4May 13, 2026
- SCHEDULE 13GMay 12, 2026
- 10-QMay 7, 2026
- 8-KMay 7, 2026
- SCHEDULE 13G/AMay 6, 2026
- SCHEDULE 13GApr 29, 2026
- SCHEDULE 13GApr 29, 2026
- 8-KApr 28, 2026
- ARSApr 28, 2026
- DEFA14AApr 28, 2026
- DEF 14AApr 28, 2026
- 144Apr 13, 2026
- 144Apr 2, 2026
- S-8Feb 26, 2026
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.